Table 1. Epidemiological, clinical, and laboratory data of the cohort of asymptomatic individuals tested during the test period of the study.

Group	Subgroup	Phase 3(n=500,914)	Subgroup for SEIR analysis(n=429)
Testing*	Positives	70,704	429
	Negatives	426,666	0
	Repeats	5,942	0
	Other	3,544	0
Specimen type	NP	32,956	429
	SG	37,508	0
	Other	71	0
Age (years)	0–4	2,013	2
	5–18	8,757	23
	19–39	31,497	271
	40–59	19,535	102
	60–79	7,518	29
	≥80	1,376	2
	Unknown	8	0
Sex	Female	37,073	206
	Male	32,733	221
	Unknown	898	2
Patient health authority	1	31,490	151
	2	9,000	4
	3	3,825	5
	4	16,394	245
	5	9,684	8
	Unknown	311	16
Vaccination status	Unvaccinated	15,494	355
	One dose	1,605	4
	Fully vaccinated†	49,361	64
	Other	4,244	6
Asymptomatic testing		1,548	429
No E gene result		18,583	0
VoC lineage	Alpha (B.1.1.7)	0	0
	Beta (B.1.351)	0	0
	Delta (B.1.617.2)	9,261	0
	Gamma (P.1)	0	0
	Omicron (B.1.1.529)	11,657	429
	Unknown ‡	49,786	0

E gene, envelope gene; VoC, variant of concern.

^*For all variables except testing, data presented as first positive result per person.

^†Does not include individuals who received ≥3 doses of vaccine.

^‡Due to laboratory testing algorithms, only a selected portion of SARS-CoV-2-positive samples underwent characterization to identify the VoC lineage.